Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 8-K

ZIOPHARM ONCOLOGY INC Form 8-K January 07, 2019

#### **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

# **CURRENT REPORT**

# **PURSUANT TO SECTION 13 OR 15(d)**

# OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 7, 2019

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction  $\begin{array}{c} \textbf{001-33038} \\ \textbf{(Commission} \end{array}$ 

84-1475642 (IRS Employer

of Incorporation)

File Number)

**Identification No.)** 

### Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 8-K

# One First Avenue, Parris Building 34, Navy Yard Plaza

# Boston, Massachusetts (Address of Principal Executive Offices) (617) 259-1970

02129 (Zip Code)

(Registrant s telephone number, including area code)

### Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

# Item 7.01 Regulation FD Disclosure.

On January 7, 2019, Ziopharm Oncology, Inc. issued a press release providing a business update.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

# Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

**Exhibit No.** Description

99.1 <u>Press release dated January 7, 2019.</u>

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2019

# ZIOPHARM ONCOLOGY, INC.

By:

/s/ Robert Hadfield Name: Robert Hadfield

Title: General Counsel and Secretary